Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current era remains unclear. We studied 286 patients with re...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2012
|
| In: |
Leukemia
Year: 2012, Volume: 26, Issue: 1, Pages: 149-157 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/leu.2011.196 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1038/leu.2011.196 Verlag, Volltext: https://www.nature.com/articles/leu2011196 
|
| Author Notes: | S.K. Kumar, J.H. Lee, J.J. Lahuerta, G. Morgan, P.G. Richardson, J. Crowley, J. Haessler, J. Feather, A. Hoering, P. Moreau, X. LeLeu, C. Hulin, S.K. Klein, P. Sonneveld, D. Siegel, J. Bladé, H. Goldschmidt, S. Jagannath, J.S. Miguel, R. Orlowski, A. Palumbo, O. Sezer, S.V. Rajkumar and B.G.M. Durie, on behalf of the International Myeloma Working Group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1582669708 | ||
| 003 | DE-627 | ||
| 005 | 20230427193256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181107s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/leu.2011.196 |2 doi | |
| 035 | |a (DE-627)1582669708 | ||
| 035 | |a (DE-576)512669708 | ||
| 035 | |a (DE-599)BSZ512669708 | ||
| 035 | |a (OCoLC)1341022264 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kumar, Shaji |e VerfasserIn |0 (DE-588)1170826083 |0 (DE-627)1040125956 |0 (DE-576)512669570 |4 aut | |
| 245 | 1 | 0 | |a Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib |b a multicenter international myeloma working group study |c S.K. Kumar, J.H. Lee, J.J. Lahuerta, G. Morgan, P.G. Richardson, J. Crowley, J. Haessler, J. Feather, A. Hoering, P. Moreau, X. LeLeu, C. Hulin, S.K. Klein, P. Sonneveld, D. Siegel, J. Bladé, H. Goldschmidt, S. Jagannath, J.S. Miguel, R. Orlowski, A. Palumbo, O. Sezer, S.V. Rajkumar and B.G.M. Durie, on behalf of the International Myeloma Working Group |
| 264 | 1 | |c 2012 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published: 29 July 2011 | ||
| 500 | |a Gesehen am 07.11.2018 | ||
| 520 | |a Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current era remains unclear. We studied 286 patients with relapsed MM, who were refractory to bortezomib and were relapsed following, refractory to or ineligible to receive, an IMiD (immunomodulatory drug), had measurable disease, and ECOG PS of 0, 1 or 2. The date patients satisfied the entry criteria was defined as time zero (T0). The median age at diagnosis was 58 years, and time from diagnosis to T0 was 3.3 years. Following T0, 213 (74%) patients had a treatment recorded with one or more regimens (median=1; range 0-8). The first regimen contained bortezomib in 55 (26%) patients and an IMiD in 70 (33%). A minor response or better was seen to at least one therapy after T0 in 94 patients (44%) including partial response in 69 (32%). The median overall survival and event-free survival from T0 were 9 and 5 months, respectively. This study confirms the poor outcome, once patients become refractory to current treatments. The results provide context for interpreting ongoing trials of new drugs. | ||
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 26(2012), 1, Seite 149-157 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib a multicenter international myeloma working group study |
| 773 | 1 | 8 | |g volume:26 |g year:2012 |g number:1 |g pages:149-157 |g extent:9 |a Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib a multicenter international myeloma working group study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/leu.2011.196 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/leu2011196 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181107 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 17 | ||
| 999 | |a KXP-PPN1582669708 |e 3030585824 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"2012","dateIssuedKey":"2012"}],"name":{"displayForm":["S.K. Kumar, J.H. Lee, J.J. Lahuerta, G. Morgan, P.G. Richardson, J. Crowley, J. Haessler, J. Feather, A. Hoering, P. Moreau, X. LeLeu, C. Hulin, S.K. Klein, P. Sonneveld, D. Siegel, J. Bladé, H. Goldschmidt, S. Jagannath, J.S. Miguel, R. Orlowski, A. Palumbo, O. Sezer, S.V. Rajkumar and B.G.M. Durie, on behalf of the International Myeloma Working Group"]},"person":[{"given":"Shaji","display":"Kumar, Shaji","role":"aut","roleDisplay":"VerfasserIn","family":"Kumar"},{"role":"aut","display":"Goldschmidt, Hartmut","given":"Hartmut","roleDisplay":"VerfasserIn","family":"Goldschmidt"}],"physDesc":[{"extent":"9 S."}],"relHost":[{"recId":"32046699X","pubHistory":["Nachgewiesen 11.1997 -"],"language":["eng"],"origin":[{"dateIssuedDisp":"1997-","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke","dateIssuedKey":"1997","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"text":"26(2012), 1, Seite 149-157","issue":"1","volume":"26","year":"2012","extent":"9","pages":"149-157"},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib a multicenter international myeloma working group studyLeukemia","note":["Gesehen am 15.03.04"],"title":[{"title":"Leukemia","title_sort":"Leukemia","subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal"}],"id":{"issn":["1476-5551"],"eki":["32046699X"],"zdb":["2008023-2"]}}],"id":{"doi":["10.1038/leu.2011.196"],"eki":["1582669708"]},"title":[{"subtitle":"a multicenter international myeloma working group study","title_sort":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib","title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib"}],"recId":"1582669708","note":["Published: 29 July 2011","Gesehen am 07.11.2018"]} | ||
| SRT | |a KUMARSHAJIRISKOFPROG2012 | ||